Protocol CP007: A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects- CATALYST

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date1/15/141/15/17

    Funding

    • inVentiv Health Clinical (CP007)
    • Circassia Ltd (CP007)